Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

In lines 9 and 10 of the left column on page 2714, "7 patients (88%)" should read "4 patients (50%)."In the next-to-last line of the right column on page 2715, "the majority (7 of 8)" should read "4."In lines 5 and 6 of the left column on page 2716, "patients who received SCT" should read "patients who did not receive SCT."The errors have been corrected in the online version of the article.